If Groucho uses a co-recruited HDAC activity to oppose β-catenin•LEF-1, is this action sufficient to counter endogenous β-catenin and its recruited histone acetyltransferase complexes in colon cancer cells? The gene discussed is HDAC9; the disease is malignant colon neoplasm.